In preclinical studies, the pan-PI3K inhibitor dactolisib, a dual ATP-competitive pan-PI3K and mTOR inhibitor, in combination with enzalutamide has been shown to effectively induce tumor regression in the MYC-overexpressing and PTEN-deficient GEM model [87]. This evidence concerns the gene PIK3CA and neoplasm.